NRIX
Nurix Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.55 / 10
Netural
Analyst sentiment is overwhelmingly positive (Strong Buy 57.1%, Buy 42.9%) with 7 active analysts, yet historical win rates vary from 0% to 57.1%, indicating inconsistency. Fund flow is rated good (7.59/10) with overall inflow ratio 0.467, but trends are negative across block, small, medium, large, and extra-large flows, hinting at short-term selling pressure despite long-term interest.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
57%
Buy
43%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-29
InstitutionRBC Capital
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for NRIX?
- NRIX holds a Bearish analyst rating, with 57% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.55/10 (Netural).
